Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH

NCT ID: NCT04610788

Last Updated: 2024-12-24

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-04-15
• Study Completion Date: 2025-12-31

Brief Summary

This observational study is being done to understand why people with scleroderma can develop pulmonary arterial hypertension (high blood pressure in the lungs, abbreviated PAH) and a weak heart muscle (heart failure). The study will also help the investigators understand why people with PAH from an unknown cause (called idiopathic PAH, or IPAH) can also develop a weakened heart muscle. The response of the right side of the heart or right ventricle (RV) to standard PAH therapy in scleroderma-associated PAH and in IPAH will be assessed. Blood and tissue samples will be collected from research participants during participants' normal standard of care procedures. People with scleroderma-associated PAH or idiopathic cause (IPAH) who need a right heart catheterization may join this study.

Detailed Description

Patients with scleroderma associated pulmonary hypertension (with or without interstitial lung disease) have a worse prognosis compared to patients with idiopathic pulmonary arterial hypertension (IPAH). The investigators have discovered through a previous protocol that patients with scleroderma associated pulmonary hypertension (SSc-PAH) have intrinsic right ventricular (RV) contractile dysfunction compared with patients with idiopathic pulmonary hypertension (IPAH) despite similar afterload imposed by the pulmonary vasculature. Patients with scleroderma or presumed/known IPAH who are clinically referred for right heart catheterization (RHC) will undergo, in addition to a clinically indicated RHC, state-of-the-art Pressure-Volume (P/V) Loop Assessment and RV biopsy for research purposes. The investigators will also do a standard pathologic assessment of the RV tissue (H&E, special staining, electron microscopy), microvascular density measurements using immunohistochemistry techniques and isolated skinned myocyte experiments. Additional experiments will include proteomics, genomics/genetics, and RV protein and microRNA expression. The investigators will compare these findings in both groups (IPAH and SSc-PAH), before and after standard treatment for 6 months, in order to fully understand the differences in how the RV adapts to pressure overload and reasons for impaired RV function in SSc-PAH as well as identifying potential therapeutic targets.

Conditions

Scleroderma; Pulmonary Artery Hypertension

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

SSc-PAH Group

Scleroderma patients referred for a clinically indicated right heart catheterization (RHC).

No interventions assigned to this group

IPAH Group

Presumed/known IPAH patients referred for a clinically indicated right heart catheterization (RHC).

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Patients 18 years or older with clinically diagnosed scleroderma or presumed/known idiopathic pulmonary hypertension.

Exclusion Criteria

• Patients found to have secondary pulmonary hypertension (PH due to left heart failure) on clinical RHC.
• Hemodynamically unstable patients (systolic blood pressure < 90mmHg, vasopressor requirement).
• Patients whom are unable to give consent for themselves.
• Patients with RV clot or septal aneurysm will be excluded.
• In order to undergo the clinical right heart catheterization procedures, pregnancy testing (urine or serum) is standard of care.
• Pregnancy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

Johns Hopkins University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Paul Hassoun, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Locations

Johns Hopkins

Baltimore, Maryland, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Paul Hassoun, MD

Role: CONTACT

Phone: 410 614 6311

Email: phassou1@jhmi.edu

Facility Contacts

Paul Hassoun, MD

Role: primary

Dezeray Cephas Dutton

Role: backup

Other Identifiers

R01HL114910-06

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NA_00049022

Identifier Type: -

Identifier Source: org_study_id